• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

SGLT2 inhibitors are antihyperglycemic drugs that protect kidneys and the heart of patients
with or without type 2 diabetes and preserved or reduced kidney function from failing. The …

SGLT2 inhibitors have emerged as a key disease-modifying therapy to prevent the
progression of chronic kidney disease (CKD). These agents prevent decline in kidney …

Sodium-glucose cotransporter 2 inhibitors (SGLT2i), a new drug class approved for
treatment of diabetes, have been shown to possess a favorable metabolic profile and to …

Background Diabetes confers an increased risk of adverse cardiovascular and renal events.
In the EMPA-REG OUTCOME trial, empagliflozin, a sodium–glucose cotransporter 2 …

Sodium-glucose cotransporter-2 (SGLT2) inhibitors, including empagliflozin, dapagliflozin,
and canagliflozin, are now widely approved antihyperglycemic therapies. Because of their …

Background The effects of empagliflozin, an inhibitor of sodium–glucose cotransporter 2, in
addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 …

Patients with type 2 diabetes mellitus are at a higher risk of developing heart failure
compared with the healthy population. In recent landmark clinical trials, sodium-glucose co …

Background The principal biological processes that characterize heart failure with a
preserved ejection fraction (HFpEF) are systemic inflammation, epicardial adipose tissue …

Over the past two years, our understanding of anti-hyperglycemic medications used to treat
patients with type 2 diabetes (T2D) has fundamentally changed. Before the EMPA-REG …